Structures of protective antibodies reveal sites of vulnerability on ebola virus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 48, 2014, Pages 17182-17187

  Murin, Charles D ^a,b   Fusco, Marnie L ^b   Bornholdt, Zachary A ^b   Qiu, Xiangguo ^c   Olinger, Gene G ^d   Zeitlin, Larry ^a   Kobinger, Gary P ^c,e   Ward, Andrew B ^a   Saphire, Erica Ollmann ^b,e  

^a Department of Integrative Structural and Computational Biology ^*  (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibodies; Ebola |; EM |; ZMapp |

Indexed keywords

EBOLA VIRUS; PRIMATES;

EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ELECTRON MICROSCOPY; IMMUNOLOGY; METABOLISM; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CELL LINE; EBOLAVIRUS; EPITOPES; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; IMMUNOGLOBULIN FAB FRAGMENTS; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; VIRAL PROTEINS;

EID: 84914127561     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1414164111     Document Type: Article

References (65)

1. Brès P (1978) [The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: Introductory note]. Bull World Health Organ 56(2):245.
2. Jahrling PB, et al. (1990) Preliminary report: Isolation of Ebola virus from monkeys imported to USA. Lancet 335(8688):502-505.
3. World Health Organization (2009) Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec 84(7):49-50.
4. Barrette RW, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325(5937):204-206.
5. Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: Evaluating the potential for clinical use. Expert Rev Vaccines 10(1): 63-77.
6. Feldmann H, et al. (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3(1):e2.
7. Geisbert TW, Bausch DG, Feldmann H (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20(6):344-357.
8. Geisbert TW, et al. (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4(11): e1000225.
9. Geisbert TW, et al. (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82(11):5664-5668.
10. Marzi A, Feldmann H, Geisbert TW, Falzarano D (2011) Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J Bioterror Biodef S1(4).
11. Côté M, et al. (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477(7364):344-348.
12. Johansen LM, et al. (2013) FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 5(190):190ra179.
13. Warren TK, et al. (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402-405.
14. Geisbert TW, et al. (2006) Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193(12): 1650-1657.
15. Geisbert TW, et al. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375(9729):1896-1905.
16. Saphire EO (2013) An update on the use of antibodies against the filoviruses. Immunotherapy 5(11):1221-1233.
17. Wong G, Qiu X, Olinger GG, Kobinger GP (2014) Post-exposure therapy of filovirus infections. Trends Microbiol 22(8):456-463.
18. Qiu X, Kobinger GP (2014) Antibody therapy for Ebola: Is the tide turning around? Hum Vaccin Immunother 10(4):964-967.
19. Dye JM, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13):5034-5039.
20. Marzi A, et al. (2012) Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7(4):e36192.
21. Zeitlin L, et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 108(51): 20690-20694.
22. Qiu X, et al. (2012) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4(138):138ra181.
23. Pettitt J, et al. (2013) Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 5(199): ra113.
24. Qiu X, et al. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47-53.
25. Hart MK, Wilson JA, Schmaljohn AL (2003) US Patent 6,630,144 B1.
26. Qiu X, et al. (2012) Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 6(3):e1575.
27. Olinger GG, Jr, et al. (2012) Delayed treatment of Ebola virus infection with plantderived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109(44):18030-18035.
28. Qiu X, et al. (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141(2):218-227.
29. Wilson JA, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287(5458):1664-1666.
30. Giritch A, et al. (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103(40): 14701-14706.
31. Strasser R, et al. (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 6(4):392-402.
32. Maruyama T, et al. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73(7):6024-6030.
33. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76(12):6408-6412.
34. Oswald WB, et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3(1):e9.
35. Marzi A, et al. (2013) Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 110(5):1893-1898.
36. Audet J, et al. (2014) Molecular characterization of the monoclonal antibodies composing ZMAb: A protective cocktail against Ebola virus. Sci Rep 4:6881.
37. Kajihara M, et al. (2012) Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol 86(24):13467-13474.
38. Dias JM, et al. (2011) A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18(12):1424-1427.
39. Lee JE, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454(7201):177-182.
40. Lee JE, et al. (2008) Complex of a protective antibody with its Ebola virus GP peptide epitope: Unusual features of a V lambda x light chain. J Mol Biol 375(1):202-216.
41. Tran EE, et al. (2014) Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J Virol 88(18):10958-10962.
42. Lee JE, Saphire EO (2009) Ebolavirus glycoprotein structure and mechanism of entry. Future Virol 4(6):621-635.
43. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF (2011) Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola viruslike particles. J Infect Dis 204(Suppl 3):S825-S832.
44. Olal D, et al. (2012) Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol 86(5):2809-2816.
45. Bale S, et al. (2012) Structural basis for differential neutralization of ebolaviruses. Viruses 4(4):447-470.
46. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y (2007) Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25(6):993-999.
47. Takada A, et al. (2003) Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 77(2):1069-1074.
48. Burton DR, Poignard P, Stanfield RL, Wilson IA (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091):183-186.
49. Julien JP, Lee PS, Wilson IA (2012) Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 250(1):180-198.
50. Bale S, et al. (2011) Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis 5(11):e1395.
51. Brecher M, et al. (2012) Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol 86(1): 364-372.
52. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308(5728):1643-1645.
53. Barrientos LG, Martin AM, Rollin PE, Sanchez A (2004) Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP. Biochem Biophys Res Commun 323(2): 696-702.
54. Sanchez A, et al. (1998) Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72(8):6442-6447.
55. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE (1998) The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250(2):408-414.
56. Basler CF (2013) A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein. Expert Rev Anti Infect Ther 11(5):475-478.
57. Mohan GS, Li W, Ye L, Compans RW, Yang C (2012) Antigenic subversion: A novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 8(12):e1003065.
58. Baize S, et al. (2014) Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371(15):1418-1425.
59. Dudas G, Rambaut A (2014) Phylogenetic analysis of Guinea 2014 EBOV Ebolavirus outbreak. PLoS Curr 6:6.
60. Calvignac-Spencer S, Schulze JM, Zickmann F, Renard BY (2014) Clock rooting further demonstrates that Guinea 2014 EBOV is a member of the Zaïre lineage. PLoS Curr 6:6.
61. Gire SK, et al. (2014) Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345(6202):1369-1372.
62. Lee JE, et al. (2009) Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. Acta Crystallogr D Biol Crystallogr 65(Pt 11): 1162-1180.
63. van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M (1996) A new generation of the IMAGIC image processing system. J Struct Biol 116(1):17-24.
64. Tang G, et al. (2007) EMAN2: An extensible image processing suite for electron microscopy. J Struct Biol 157(1):38-46.
65. Pettersen EF, et al. (2004) UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem 25(13):1605-1612.